TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04206332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.
Study: NCT00916734

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MDT (McKenzie Method)
Description: Subjects who perform exercises in their direction of preference.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal thrust manipulation
Description: Subjects who receive spinal thrust manipulation as an intervention.
Study: NCT00090428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten- and casein-free diet
Description: Participants will follow a gluten-free and casein-free diet for 18 weeks. All children received individual EIBI interventions to decrease the confound of different types of therapies.
Study: NCT04206332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Intervention type: OTHER
Group type: OTHER
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).
Study: NCT01262898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (5 mg tablet)
Description: 5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (25 mg tablet)
Description: 25 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (25 mg tablet)
Description: 25 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (125 mg tablet)
Description: 125 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (125 mg tablet)
Description: 125 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet
Study: NCT04073667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Specific Exercises:~a. Exercises for cervical flexors: Objectives are summarized below:~* To increase the endurance and strength of cervical flexors. b. Exercises for cervical extensors:~* Training of craniocervical extensors and rotators with the cervical spine in the neutral position, c. Axiocapular muscles;~* Teaching the correct scapular position, D. Postural correction exercises;~* Teaching the neutral spine position from the first treatment session, 2) Sensorimotor Exercises:~  a. Joint position sense:~* Participants are trained to point their heads in different directions with the help of an illuminated band that is attached to the head with the eyes open at the beginning.~  b. The sense of cervical movement, c. Oculomotor control exercises, 3) Balance and coordination exercises;~  a. Balance training starts with static balance exercises and continues with dynamic balance exercises and walking exercises with different difficulty.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Specific Exercises:~a. Exercises for cervical flexors: Objectives are summarized below:~* To increase the endurance and strength of cervical flexors. b. Exercises for cervical extensors:~* Training of craniocervical extensors and rotators with the cervical spine in the neutral position, c. Axiocapular muscles;~* Teaching the correct scapular position, D. Postural correction exercises;~* Teaching the neutral spine position from the first treatment session, 2) Sensorimotor Exercises:~  a. Joint position sense:~* Participants are trained to point their heads in different directions with the help of an illuminated band that is attached to the head with the eyes open at the beginning.~  b. The sense of cervical movement, c. Oculomotor control exercises, 3) Balance and coordination exercises;~  a. Balance training starts with static balance exercises and continues with dynamic balance exercises and walking exercises with different difficulty.
Study: NCT02599402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT00828451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [5,5,5-2H3]leucine (stable isotope labeled leucine)
Description: intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
Study: NCT04857021

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GABA
Description: oral administration of GABA capsule once daily before sleep

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo capsule once daily before sleep
Study: NCT02233842

Intervention type: BEHAVIORAL
Intervention: Participant interview
Description: People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
Study: NCT02514044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexedrine
Description: 10 mg immediate release of Dexedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexedrine
Description: 10 mg immediate release of Dexedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexedrine
Description: 10 mg immediate release of Dexedrine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 1.5 mA tDCS anodal tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 1.5 mA tDCS anodal tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 1.5 mA tDCS anodal tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 1.5 mA tDCS anodal tDCS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: 60 min of speech therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: 60 min of speech therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: 60 min of speech therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: 60 min of speech therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: 60 min of speech therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: 60 min of speech therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Study: NCT02052102

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Study: NCT03386045

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Optimal SBRT
Description: Two thirds of the participants in this group will get the SBRT (5 treatments) and one third will get standard treatment (60 Gy in 20 treatments)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Booster
Description: Two thirds of the participants in this group will get the two high precision radiotherapy plus 20 doses of standard external beam radiotherapy (ie the Booster approach\|) and one third will get the standard treatment (60 Gy in 20 treatments)
Study: NCT00090428

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo controlled diet
Description: Participants will follow a gluten-free and casein-free diet for 18 weeks. They will receive double blind placebo controlled challenge snacks that contain gluten, casein, gluten+casein or placebo with measurement of response. They remain on the gluten free and casein free diet for the entire study period.
Study: NCT02512419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-Enhanced Physical Activity Intervention Arm
Description: Participants in the Text-Enhanced Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, print-based + text-message physical activity intervention that specifically addresses the physical activity barriers and intervention needs/preferences of Mexican and Mexican American men.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control Arm
Description: Participants will receive a Spanish language, print-based Wellness Contact control intervention addressing relevant health topics other than physical activity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Actigraph GT3X

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph GT3X
Study: NCT00400478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
Study: NCT02052102

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Study: NCT02780791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation into pelvic wall
Description: Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
Study: NCT02294942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RANCAD
Description: Extended-Release RANCAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RANCAD
Description: Extended-Release RANCAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RANCAD
Description: Extended-Release RANCAD
Study: NCT02780791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation into the ovary
Description: Ovarian tissue will be transplanted contralateral into the ovary.
Study: NCT01904773

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD5213 and placebo
Description: low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213 and placebo
Description: low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213 and placebo
Description: low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
Study: NCT00353470

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: CBT for panic disorder will include 19 to 24 sessions over 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied relaxation training (ART)
Description: ART with exposure protocol will include 19 to 24 sessions over 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Panic focused psychodynamic psychotherapy (PFPP)
Description: PFPP will include 19 to 24 sessions over 12 weeks.
Study: NCT03381742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: ticagrelor 45 mg twice daily for 5 consecutive days at least.
Study: NCT03841981

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical, hormonal and metabolic phenotyping
Description: * Lipid profile.~* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~* Sex steroid profile.~* Hypothalamic-pituitary-adrenal axis study.~* Ferrokinetic study.~* Subclinical chronic inflammatory markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical, hormonal and metabolic phenotyping
Description: * Lipid profile.~* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~* Sex steroid profile.~* Hypothalamic-pituitary-adrenal axis study.~* Ferrokinetic study.~* Subclinical chronic inflammatory markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical, hormonal and metabolic phenotyping
Description: * Lipid profile.~* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~* Sex steroid profile.~* Hypothalamic-pituitary-adrenal axis study.~* Ferrokinetic study.~* Subclinical chronic inflammatory markers.
Study: NCT01321047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol (0.5 mg/kg body weight; 10 mg if age \> 70 or ASA class III-IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPS
Description: midazolam (0.05 mg/kg body weight; 1 mg if age \> 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age \> 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
Study: NCT01276886

Intervention type: DRUG
Intervention: antibiotic

Intervention type: PROCEDURE
Intervention: Colonic resection with or without stoma
Study: NCT04117750

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (vit D3)
Description: 42,000 IU oral vitamin D per week and 500 mg calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol (vit D3)
Description: 42,000 IU oral vitamin D per week and 500 mg calcium carbonate
Study: NCT01075087

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bilateral TAP block using sterile normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
Description: (study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
Study: NCT02436109

Intervention type: DEVICE
Intervention: Ultrasound
Description: Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
Study: NCT03381742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: ticagrelor 90 mg once daily for 5 consecutive days at least.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: ticagrelor 90 mg twice daily for 5 consecutive days at least.
Study: NCT04177303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants will be randomized to metformin 2000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to placebo
Study: NCT02945982

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir+Carvedilol
Description: The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir+Carvedilol+ Fuzheng Huayu
Description: The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
Study: NCT02060734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
Study: NCT04206332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).

Intervention type: OTHER
Group type: OTHER
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).

Intervention type: OTHER
Group type: OTHER
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).
Study: NCT04195360

Intervention type: OTHER
Intervention: Standardized mobilization procedure
Description: 5 minutes bed rest (h1), followed by 3 minutes passive leg raise (PLR), followed by 5 minutes bed rest (h2), followed by 3 minutes sitting on the egde of the bed (sit), followed by 3 minutes standing/walking on the spot (sta), followed by 5 minutes bedrest (h3)

Intervention type: OTHER
Intervention: Standardized mobilization procedure
Description: 5 minutes bed rest (h1), followed by 3 minutes passive leg raise (PLR), followed by 5 minutes bed rest (h2), followed by 3 minutes sitting on the egde of the bed (sit), followed by 3 minutes standing/walking on the spot (sta), followed by 5 minutes bedrest (h3)